A share price of Xenon Pharmaceuticals Inc [XENE] is currently trading at $38.90, down -1.14%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The XENE shares have lost -1.39% over the last week, with a monthly amount glided 0.13%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright started tracking the stock with Buy rating on October 01, 2024, and set its price target to $53. On January 04, 2024, Citigroup initiated with a Buy rating and assigned a price target of $62 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $63 on December 08, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on April 25, 2023, and assigned it a price target of $58. In a note dated December 14, 2022, Goldman initiated an Buy rating and provided a target price of $60 on this stock.
Xenon Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $35.53 and $50.99. Currently, Wall Street analysts expect the stock to reach $50.67 within the next 12 months. Xenon Pharmaceuticals Inc [NASDAQ: XENE] shares were valued at $38.90 at the most recent close of the market. An investor can expect a potential return of 30.26% based on the average XENE price forecast.
Analyzing the XENE fundamentals
Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at -47.49%, Pretax Profit Margin comes in at -39.75%, and Net Profit Margin reading is -39.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.25 and Total Capital is -0.32.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 37.76 points at the first support level, and at 36.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 39.81, and for the 2nd resistance point, it is at 40.71.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Xenon Pharmaceuticals Inc [NASDAQ:XENE] is 22.21. In addition, the Quick Ratio stands at 22.21 and the Cash Ratio stands at 2.95.
Transactions by insiders
Recent insider trading involved AULIN SHERRY, Chief Financial Officer, that happened on Dec 18 ’24 when 18709.0 shares were sold. Officer, SHERRY AULIN completed a deal on Dec 18 ’24 to buy 18709.0 shares. Meanwhile, Director PATOU GARY sold 4891.0 shares on Nov 22 ’24.
